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The Naþ/Ca2þ exchanger (NCX) plays a major role in myocardial Ca2þ homoeostasis, but is also con-
sidered to contribute to the electrical instability and contractile dysfunction in chronic atrial ﬁbrillation
(AF). Here we have investigated the effects of the selective NCX blocker SEA0400 in human right atrial
cardiomyocytes from patients in sinus rhythm (SR) and AF in order to obtain electrophysiological evi-
dence for putative antiarrhythmic activity of this new class of drugs. Action potentials were measured in
right atrial trabeculae using conventional microelectrodes. Human myocytes were enzymatically iso-
lated. Rat atrial and ventricular cardiomyocytes were used for comparison. Using perforated-patch, NCX
was measured as Ni2þ-sensitive current during ramp pulses. In ruptured-patch experiments, NCX cur-
rent was activated by changing the extracellular Ca2þ concentration from 0 to 1 mM in Naþ-free bath
solution (100 mM Naþ intracellular, “Hilgemann protocol”). Although SEA0400 was effective in rat car-
diomyocytes, 10 mM did not inﬂuence action potentials and contractility, neither in SR nor AF. SEA0400
(10 μM) also failed to affect human atrial NCX current measured with perforated patch. With the “Hil-
gemann protocol” SEA0400 concentration-dependently suppressed human atrial NCX current, and its
amplitude was larger in AF than in SR cardiomyocytes. Our results conﬁrm higher NCX activity in AF than
SR. SEA0400 fails to block Ni2þ-sensitive current in human atrial cells unless unphysiological conditions
are used. We speculate that block of NCX with SEA0400 depends on intracellular Naþ concentration.
& 2016 Elsevier B.V. All rights reserved.1. Introduction
The Naþ/Ca2þ exchanger (NCX) is the major Ca2þ extruding
process in mammalian myocardium and therefore plays a domi-
nant role in cardiac Ca2þ homoeostasis (Bers, 2002; Sipido, 2000).
Because of its electrogenic nature it contributes to transmembrane
potential. Negative to the reversal potential, the transmembrane
concentration gradient for Naþ is driving Ca2þ out of the cell
(“forward mode”) resulting in net inward (depolarising) current.U Dresden, Fetscherstr. 74,
med.u-szeged.hu (K. Acsai),
),
zote.u-szeged.hu (N. Jost),When operating in the “reverse” mode, NCX allows Ca2þ to enter
the cell, producing net outward (repolarizing) current. The anti-
porter's activity thus modulates both electrical activity and in-
tracellular Ca2þ concentration [Ca2þ]i [for review see (Antoons
et al., 2012)].
Increased activity of NCX is proarrhythmic, irrespective of up-
regulation by genetic manipulation (Pott et al., 2012) or due to
pathophysiological alterations in hypertrophy and heart failure
(Antoons et al., 2012; Hasenfuss et al., 1996; Pogwizd et al., 2001;
Sipido, 2000; Bers and Despa, 2006). Remodelling processes as-
sociated with chronic atrial ﬁbrillation include upregulation of
NCX at mRNA and protein level (El Armouche et al., 2006;
Schotten et al., 2002; Voigt et al., 2012). The associated NCX ac-
tivity increase contributes to the observed electrical instability and
contractile dysfunction (Dobrev and Wehrens, 2010). Abnormal
Ca2þ signalling in AF is recognised as a major pathophysiological
cause of triggered activity and maintenance of AF (Dobrev and
Nattel, 2008; Lugenbiel et al., 2015; Wakili et al., 2011) with in-
creasing evidence for enhanced diastolic Ca2þ leak from
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2005; Voigt et al., 2012), although there is also evidence not
supporting such view (Greiser et al., 2014). The upregulated NCX
exchanges diastolic leak Ca2þ for Naþ giving rise to depolarising
transient inward currents and increasing the susceptibility to
cellular delayed afterdepolarizations and triggered activity (Voigt
et al., 2012).
Compounds that selectively block NCX have fuelled great ex-
pectations as antiarrhythmic agents by stabilizing the membrane
potential and ameliorating contractile dysfunction (Iwamoto et al.,
2007; Pogwizd, 2003). The NCX blocker SEA0400 possesses good
selectivity for NCX over ion channels especially L-type Ca2þ
channels (Birinyi et al., 2005; Hobai et al., 1997; Matsuda et al.,
2001; Tanaka et al., 2002), however at high concentrations of
43 μM this may no longer be the case (Birinyi et al., 2005).
SEA0400 inhibits NCX both in its forward and reverse mode in
expression systems and cardiomyocytes of different species (Ta-
naka et al., 2002) and possesses antiarrhythmic activity in various
animal models of arrhythmia (Nagasawa et al., 2005; Nagy et al.,
2004, 2014; Szepesi et al., 2015). However, no information is
available for SEA0400 in human atria.
In order to evaluate SEA0400 as a putative antiarrhythmic
agent for atrial ﬁbrillation (AF), we have investigated its effects in
atrial biopsies obtained from patients in sinus rhythm, chronic AF
and paroxysmal AF. Cardiomyocytes from atria and ventricles of
rat hearts were used for comparative purposes. Although NCX
current amplitudes were higher in samples from AF than from SR
patients, SEA0400 inhibited human atrial NCX current only under
conditions of high intracellular Naþ .2. Material and methods
2.1. Tissue samples and cell isolation
Biopsies from right atrial appendages were obtained from adult
patients undergoing open-heart surgery. The study was approved
by the ethics committee of the Medical Faculty of Technical Uni-
versity Dresden, Germany (No. EK790799). Each patient gave
written, informed consent.
All experiments with rat cardiomyocytes were performed in
accordance with the local authorities (permission number 24D-
9168.24-1/2007-17 of the Regierungspräsidium Dresden) and
comply with the European Commission Directive 86/609/EEC re-
garding the protection and welfare of animals used for experi-
mental as well as scientiﬁc purposes. The rats were killed by de-
capitation under light CO2 anaesthesia (70% CO2, 30% O2). The
hearts were excised and mounted on a Langendorff perfusion
column by tying the aorta to the outﬂow cannula. The remaining
blood in the hearts was washed out with normal, oxygenated
Tyrode solution at 37 °C (5 min). The solution was then changed to
nominally Ca2þ-free solution for 10 min before the solution was
supplemented with enzymes containing collagenase (Type I,
Worthington, 233 units/mg; 0.54 mg/ml) and 1% BSA (Sigma).
After 10–15 min, the hearts were removed from the Langendorff
apparatus. The atria and ventricles were separated, minced into
small chunks and further processed like human cardiomyocytes
until single cardiomyocytes with clear cross striations appeared in
the suspension.
Cardiomyocytes were isolated from right atrial biopsies as de-
scribed previously (Dobrev et al., 2000). In brief, the tissue was cut
into small pieces in Ca2þ-free isolation buffer of the following
composition (in mM): NaCl 100, KCl 10, KH2PO4 1.2, MgSO4 5,
MOPS 5 mM, mM, glucose 20, taurine 50 (pH ¼7.0), and washed
3 times for 3 min. During the complete isolation procedure, the
solutions were oxygenated with 100% O2 at 35 °C. For enzymaticdissociation of the tissue pieces, 246 U/ml collagenase type I
(Worthington Biochemical Corp., NJ, USA) and 0.5 mg/ml protease
type XXIV (Sigma-Aldrich Co., St Louis, USA) were added to the
nominally Ca2þ- free buffer. After gentle stirring for 10 min,
0.2 mM Ca2þ was added, and the tissue was stirred for another
35 min. Solution was changed and the digestion was continued
with 246 U/ml collagenase type I in the presence of 0.2 mM Ca2þ .
Stirring of the solution containing the tissue fragments was stop-
ped when single rod-shaped, striated myocytes could be detected
in test droplets under the microscope. The suspension was cen-
trifuged, myocytes were resuspended and stored until use in Tyr-
ode's solution (supplemented with 0.5 mM Ca2þ in three steps) at
room temperature.
2.2. Perforated patch-clamp experiments
Perforated patch-clamp experiments were performed on single
myocytes within 1–5 h after cell isolation. A gigaohm seal was
established using borosilicate glass pipettes (R¼2–3 MΩ) in Kþ
free Tyrode's solution [composition in mM/l: Na-methanesulfonic
acid 140, MgCl2 1, BaCl2 0.2, CaCl2 1, glucose 10, HEPES 10, (pH
adjusted to 7.4 with NaOH)] at 37 °C. The bath was superfused
with Tyrode's solution supplemented with 20 μM ouabain, 1 μM
nisoldipine and 50 μM lidocaine in order to block Naþ/Kþ pump
currents, as well as L-type Ca2þ and Naþ currents. Amphotericin B
(SIGMA-Aldrich Co.) was solved in 98% ethanol and sonicated for
25 min at room temperature (c¼40 mg/ml). Stock solution was
stored at 4 °C for a maximum of 1 week. 240 μg/ml amphotericin B
was added to the pipette solution before the start of the experi-
ments. Pipette solution [composition in mM/l: CsOH 150, NaOH 10,
HEPES 10, MgCl2 1, CaCl2 10 μM, aspartic acid 75 mM (pH¼7.2)]
was sonicated for 10 min and was kept on ice. Intracellular Ca2þ
concentration was calculated to be 165 nM in this pipette solution
by WEBMAXCLITE v1.15 software (Chris Patton, Stanford Uni-
versity, CA, USA). Fresh pipette solution was prepared in every 2 h.
INCX was recorded with the protocol reported by (Hobai et al.,
1997). Ramp pulses (100 mV/s) were delivered at a rate of 0.05 Hz.
The membrane was depolarised from the holding potential of
40 mV to þ60 mV, then hyperpolarized to 100 mV, ﬁnally the
membrane potential returned to the holding potential. Outward
and inward INCX were determined during the descending limb of
the ramp. After the control record was taken, the cell was super-
fused with the given concentration of SEA0400, ﬁnally 10 mM
NiCl2 was added in order to fully block INCX. Total INCX was de-
termined as a Ni2þ-sensitive current.
Extracellular application of agents was performed through a
DAD Superfusion System (ALA Scientiﬁc Instruments, New York,
USA). Standard voltage clamp experiments were conducted with a
single electrode patch clamp system using an Axopatch 200B
ampliﬁer (MDS Analytical Technologies, Toronto, Canada), a TC-
344B dual automatic temperature controller and data storage de-
vices. Current signals were low-pass ﬁltered at 1–3 kHz by the
ampliﬁer, digitised, saved and analysed with the patch-clamp
software ISO-2 (MFK-Computer, Niedernhausen, Germany).
2.3. Whole-cell patch-clamp experiments (reverse mode NCX
activation)
Whole-cell conﬁguration of the patch-clamp method was es-
tablished in superfusion buffer of the following composition (in
mM): LiCl 135, CsCl 10, NaH2PO4 0.33, MgCl2 1, BaCl2 0.2, TEA-Cl
10, glucose 10, HEPES 10, EGTA 0.5 (pH¼7.4). Lidocaine (50 μM),
nisoldipine (1 μM) and ouabain (20 μM) were added to block Naþ
channels, L-type Ca2þ channels and the (Naþþ Kþ)-ATPase, re-
spectively. The pipette solution contained (in mM): NaOH 100,
CsOH 20, CaCl2 13, MgCl2 1.1, TEA-Cl 20, EGTA 50, MgATP 4, HEPES
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to be 105 nM (WEBMAXCLITE v1.15 software).
INCX was recorded at a holding potential of 40 mV. Outward
INCX was activated by applying 1 mM Ca2þ extracellularly for 20 s.
The bath was perfused again with Ca2þ-free solution for 3 min
before the second current activation. Myocytes were treated for
3 min with different concentrations of SEA0400 before exposed
once more to 1 mM Ca2þ under control conditions, in the presence
of SEA0400, or 10 mM Ni2þ .
2.4. Contractility measurements
Right atrial trabeculae were mounted in organ baths ﬁlled with
50 ml of Tyrode solution. The preparations were paced at a fre-
quency of 1 Hz, with 5-ms electrical pulses 10% above threshold
intensity and were pre-stretched to 50% of maximum developed
force. All preparations were exposed for 90 min to the non-spe-
ciﬁc, irreversible α-adrenoreceptor blocker phenoxybenzamine
(PBA, 6 μM) in order to minimise stimulation of α-adrenoceptors
via catecholamines released from endogenous sympathetic nerve
endings. PBA was washed by removal of old and addition of fresh
bath solution. After an equilibration period of 30 min, the effects of
SEA0400 or of an equivalent amount of DMSO (0.1%) as time-
matched control were measured on contractile force, recordings of
which were saved on a personal computer and analysed off-line by
Chart (Version 5.5, AD Instruments Pty Ltd., Castle Hill, NSW,
Australia) software. Data was plotted by Prism (Version 4.00,
GraphPad Software, Inc., San Diego, USA) software.
2.5. Conventional microelectrode technique
Human right atrial trabeculae muscles were mounted in an
organ bath perfused with oxygenated Tyrode's solution. The pre-
parations were stimulated electrically via silver/silver chloride
electrodes at a regular frequency of 1 Hz. The muscles were al-
lowed to equilibrate for at least 90 min before intracellular action
potentials were recorded with borosilicate glass pipettes, ﬁlled
with 2.5 M KCl solution (tip resistances were 20–30 MΩ). Drugs
were added to the superfusing solution from concentrated stock
solutions to yield the ﬁnal concentration. Action potentials from
stable preparations were recorded 20 min after drug addition by
HSE-APES software (Department of Pharmacology, Albert Szent-
Gyorgyi Medical University, Szeged, Hungary). Action potentials
were stored on a personal computer, and the main parameters
were analysed off-line, data was plotted by Prism (Version 4.00,
GraphPad Software, Inc., San Diego, USA) software.
2.6. Drugs
SEA0400 (2-[4-[(2,5-diﬂuorophenyl)methoxy]phenoxy]5-
ethoxy-aniline) was synthesised by Ferenc Fülöp (Institute of
Pharmaceutical Chemistry, University of Szeged, Hungary). The
product was isolated as hydrochloride salt. A stock solution of
SEA0400 (10 mM) was prepared in 100% DMSO, aliquots of which
were stored at –20 °C. All other chemicals and drugs were ob-
tained from Sigma Chemicals.
2.7. Statistical analysis
Statistical signiﬁcance between groups was analysed by paired
or unpaired Student's t-test, where appropriate. Data is expressed
as mean7S.E.M., numbers of experiments (n) are given as cells/
patients.3. Results
3.1. Effects of SEA0400 on action potentials and force of contraction
In a ﬁrst set of experiments the effects of SEA0400 on action
potentials and force of contraction were examined in human right
atrial trabeculae stimulated at 1 Hz (Fig. 1). Under control condi-
tions, action potentials from patients in SR and AF had the typical
“spike-and-dome” and triangular appearance, respectively (Dobrev
and Ravens, 2003). However, increasing concentrations between
0.1 and 10 μM of SEA0400 did not produce any signiﬁcant changes,
neither in comparison with pre-drug controls nor with a group of
preparations treated with solvent only that served as time-mat-
ched controls. In addition, 10 μM of SEA0400 or 0.1% of DMSO had
no effect on force of contraction. Since lack of efﬁcacy in super-
fused multicellular preparations could be due to impaired drug
diffusion within the tissue, we tested the efﬁcacy of SEA0400 on
NCX current measured in isolated cardiomyocytes.
3.2. Ramp protocol for activation of NCX
At experimental conditions that strongly reduce interfering
currents conducted via Naþ , Kþ and Ca2þ channels as well as Naþ
pump current, human atrial cardiomyocytes exhibited robust in-
ward and outward currents during the ramp protocol (Fig. 2), ir-
respective of whether the cells were derived from patients in SR or
AF (Fig. 2A and C). SEA0400 (3 μM) had no effect, whereas addi-
tion of nickel (10 mM) partially reduced current amplitude. Fig. 2B
and D show average SEA0400- and Ni2þ-sensitive currents in pA/
pF of cells from SR and AF patients. The absolute NCX current
densities at membrane potentials relevant for the action potential,
i.e. at 60 mV and 40 mV were 0.8270.15 pA/pF, and
0.5170.10 pA/pF, respectively, in AF and 0.4070.12 pA/pF
and 0.2770.08 pA/pF, respectively, in SR. Although current
density tended to be larger in AF than in SR, the differences failed
to reach the level of statistical signiﬁcance. SEA0400 had no effect
on NCX current measured with this technique, although a robust
SEA0400-sensitive current was detected in rat ventricular myo-
cytes (see Supplementary Fig. 1).
3.3. NCX activity using the “Hilgemann protocol”
The group of Hilgemann introduced a method for activating
NCX, by rapidly changing the ionic compositions of the extra-
cellular bath solution [Fig. 3A; (Hilgemann et al., 1992a, 1992b)].
With the membrane potential clamped to 10 mV (ruptured
patch), a large, reversible outward current was recorded when
rapidly changing [Ca2þ]e from 0 to 1 mM and back to 0, i.e. by
activating NCX in its reverse mode (“Hilgemann protocol”). Such
currents could be repeatedly activated also in human atrial car-
diomyocytes and were almost completely suppressed by 10 mM
Ni2þ (Fig. 3B). The inactivation of NCX current during the 20-s
period of superfusion with 1 mM Ca2þ was not analysed any fur-
ther. Average peak reverse mode NCX current density was larger in
AF than in SR cells, did not change signiﬁcantly in TMC, but was
highly signiﬁcantly suppressed not only by 10 mM Ni2þ but also
by 300 nM SEA0400 (Fig. 3C and D). The inhibitory effect of
SEA0400 on NCX current measured with the “Hilgemann protocol”
was concentration-dependent and complete (Fig. 4A to C). No
differences in -logEC50 values for SEA0400 were detected between
cardiomyocytes from SR and AF patients, i.e. 6.77 and 6.86, re-
spectively. In rat ventricular cardiomyocytes, 10 μM SEA0400 also
completely suppressed NCX current (Fig. 4C).
Peak current density measured with the Hilgemann protocol
reveal 40% higher values in atrial cardiomyocytes from patients
in AF than in from patients in SR (Fig. 4D). We also had the chance
Fig. 1. Effects of SEA0400 on action potentials and force of contraction in human right atrial trabeculae from patients in sinus rhythm (SR) and atrial ﬁbrillation (AF). A and B:
action potential tracings at pre-drug control and after 20 min of superfusion with cumulatively increasing concentrations of SEA0400 (0.1–10 μM). C and D: Comparison of
concentration-response curves for the effects of SEA0400 on action potential duration at 90% of repolarization (APD90) with time-matched controls (TMCs). E and F: Force of
contraction in mN (Fc) before and 30 min after addition of solvent (DMSO 0.1%) or SEA0400 (10 μM). Mean values7S.E.M. from n trabeculae (action potentials) or number of
trabeculae/number of patients (force).
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AF, in which NCX current density was comparable to the values of
SR patients, however, we were not successful investigating
SEA0400 effects in paroxysmal AF. Rat atrial cardiomyocytes
showed signiﬁcantly larger amplitudes of NCX current density
than rat ventricular cells.4. Discussion
The major ﬁndings of our present study were that (i) INCX
measured with 2 independent protocols is of larger amplitude in
cells from AF than from SR patients; (ii) SEA0400 did not modulate
action potentials of atrial trabeculae from patients, neither in SR
nor with AF; (iii) NCX current was detected as Ni2þ-sensitive
current in patch-clamped atrial myocytes during ramp pulses, but
SEA0400 had no effect neither on forward nor reverse mode NCX;
(iv) SEA0400 was able to suppress NCX current activated by re-
verse mode NCX activity at 10 mV under unphysiological intra-
and extracellular Naþ and Ca2þ concentrations.
4.1. Lack of effect of SEA0400 on action potentials of human atrial
trabeculae
Since the antiporter is controlled by membrane potential and
the concentration gradients for Ca2þ and Naþ , the time course ofNCX current during an action potential is complicated, and simu-
lation models of the exchanger help to predict it (Blaustein and
Lederer, 1999; Hilgemann, 2004; Pogwizd et al., 2003). When
considering only potential-dependence, NCX current is expected
to affect the cardiac action potential in a different way (Fig. 5A)
than when considering only changes in cardiac concentration
gradient (Fig. 5B), depending on the membrane potential. In its
reverse mode during the early plateau phase, net outward NCX
current will shorten action potential duration, whereas in the
forward mode during late repolarisation, inward NCX current will
delay ﬁnal repolarization. For NCX blockers, the opposite changes
are anticipated with early prolongation and late shortening. To
our surprise we did not observe any effects at all on atrial action
potentials even with SEA0400 concentrations as high as 10 μM,
which completely blocked NCX current in expression systems. It
should be noted, however, that at such high concentrations
SEA0400 may no longer be selective for inhibition of NCX but
also block L-type Ca2þ channels (Birinyi et al., 2005), which is
expected to shorten the action potential. At the time of our study,
the more selective NCX blockers were not available to us
(Jost et al., 2013).
Amongst the many possible causes for this lack of effect we
could exclude chemical inactivation of the compound because
action potentials were shortened in rat myocardium (unpublished
result). Another reason could have been that SEA0400 cannot
penetrate multicellular tissue because of diffusion barriers.
Fig. 2. NCX currents in human right atrial cardiomyocytes from patients in sinus rhythm (SR) and atrial ﬁbrillation (AF). A and C: Current traces elicited by a 3-s double ramp
pulse from a holding potential of 40 mV to þ60 mV, to 100 mV and back to 40 mV (see inset) at pre-drug control (black traces), and after 2 min of superfusion of an SR
(A) and an AF (C) cardiomyocyte in the presence of SEA0400 (3 μM, blue traces) and after further 2 min of superfusion with Ni2þ (10 mM, green traces). B and D: Mean
values7S.E.M of SEA0400- (blue) and Ni2þ-sensitive (green) current density expressed in pA/pF in 21 cardiomyocytes from 10 SR and 4 cardiomyocytes from 3 AF-patients.
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cellular tissue than in single cardiomyocytes SEA0400 was re-
ported to be active in ventricular tissue of various species (Nagy
et al., 2014). A chamber speciﬁc effect, i.e. atria versus ventricle,
could also be excluded because SEA0400 shortened action po-
tentials both in atrial and ventricular strips of rat hearts. Last not
least, we considered that SEA0400 might be ineffective because
the NCX contributes very little current to the human atrial action
potential, despite of several reports suggesting a pathophysiolo-
gical role of NCX in triggering and maintaining atrial ﬁbrillation
(Schotten et al., 2011; Voigt et al., 2012). Therefore NCX currents
were measured directly in human atrial cardiomyocytes.
4.2. Lack of SEA0400 effect in NCX recorded with a ramp protocol
To the best of our knowledge, INCX currents have not previously
been reported for native human atrial cardiomyocytes neither
from patients in AF nor in SR. This may not hold true for human
ventricular cardiomyocytes. Voigt et al. (2012) reported differences
between AF and SR cells by comparing the decay rate of transient
outward current after caffeine-induced Ca2þ release from the
sarcoplasmic reticulum, and did not report any drug effects. The
standard ramp protocol for measuring NCX current (Hobai et al.,
1997) yielded Ni2þ-sensitive current in human atrial myocytes,
indicating that a robust NCX current is also present in human atria.
Moreover, current density was larger in cells from patients in AF
than in SR. Yet again, SEA0400 did not affect Ni2þ-sensitive cur-
rent neither in myocytes from SR nor AF patients. This was again a
surprising ﬁnding, since SEA0400 inhibited NCX current in rat
atrial and ventricular myocytes also in our hands [Supplementary
Fig. 1].4.3. Block of NCX current by SEA0400 in human atrial myocytes in
its reverse mode (“Hilgemann protocol”)
In our ﬁnal set of experiments with high [Naþ]i and zero
[Naþ]e and zero [Ca2þ]e we measured large amplitude, Ni2þ-
sensitive outward currents upon switching to 1 mM [Ca2þ]e,
which slowly inactivated partially during superfusion with 1 mM
[Ca2þ]e. The time course of the current was not considered any
further, and only peak current amplitude was analysed. In analogy
to the work by Hilgemann and coworkers we deﬁne peak current
as “reverse mode” NCX current amplitude (Hilgemann et al., 1992a,
1992b). Our results indicate larger NCX current amplitude in AF
than SR myocytes, which is consistent with the increased ex-
pression of NCX in remodelled atria both at mRNA and protein
level (El Armouche et al., 2006; Schotten et al., 2002; Voigt et al.,
2012). Interestingly, myocytes from patients in paroxysmal AF had
NCX amplitudes similar to SR supporting the general notion that
little electrical remodelling takes place in myocytes from these
patients (Loose et al., 2014). Reverse-mode NCX currents activated
with the “Hilgemann protocol” were inhibited by SEA0400 in a
concentration-dependent manner indicating that SEA0400 can in
fact block NCX current also in human atrial myocytes, albeit under
special conditions. Only when the reverse mode was enforced by
reversing the Naþ concentration gradient, but not by membrane
potential (see Fig. 5), could we detect efﬁcacy of SEA0400, sug-
gesting that high [Naþ]i is required for efﬁcacy. We therefore
speculate that the NCX-blocking effect of SEA0400 strongly de-
pends on the [Naþ]i, which is substantially higher in rat [17 mM,
for references, see (Lewalle et al., 2014)] than in human myo-
cardium [8 mM (Hoey et al., 1994)]. This idea is supported by a
recent report on the potency of SEA0400 block of NCX1.1 ex-
pressed in Xenopus oocytes. The concentration-response curve for
Fig. 3. Effects of Ni2þ and SEA0400 on NCX currents measured with the “Hilgemann protocol”. A: Scheme of Naþ and Ca2þ concentrations in the extracellular superfusion
and intracellular (pipette) solutions. B: NCX current was activated by changing the extracellular Ca2þ from 0 to 1 mM Ca2þ for 20 s. The third change of extracellular Ca2þ
was carried out in the presence of 10 mM Ni2þ . NCX amplitude was measured as peak current (arrow). C and D: NCX current density in time-matched controls (TMCs), in the
presence of Ni2þ (10 mM) or SEA0400 (10 μM) in cardiomyocytes from SR or AF patients. Mean values7S.E.M. from number of cells/number of patients as indicated.
Fig. 4. Concentration-dependent block of NCX by SEA0400. A and B: Outward current during a 20 s of stimulation of NCX in backward mode (“Hilgemann protocol”, see
Fig. 3) under control conditions (black, red) and in the presence of SEA0400 (100 nM, blue) in a SR (A) and an AF cardiomyocyte (B). C: Concentration-dependent effect of
SEA0400 on NCX current in SR and AF cells, and effect of 10 μM SEA0400 on NCX in rat atrial cardiomyocytes (note that the latter point was shifted by 0.2 log units to the
right on the graph for better visibility). D: Amplitudes of NCX measured as Ni2þ-sensitive current with the “Hilgemann protocol” in human atrial cardiomyocytes from
patients in SR, AF and paroxysmal AF (pAF), and in atrial and ventricular cardiomyocytes from rat hearts. Mean values7S.E.M. from number of cells /number of patients or
animals as indicated by the numbers at the base of the columns. *** Po0.001, Student's t-test between columns.
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Fig. 5. Scheme of changes in NCX activity (i.e. current amplitude) by enhanced
expression (A) or by changes in ion concentrations (B) and their expected inﬂuence
on the shape of human atrial action potentials. The I/V curves (arbitrary current
units) were calculated according to the formula given by (Sipido et al., 2006). The
lay-out was adapted from (Ravens and Wettwer, 1989). The coloured downward
and upward arrows indicate increases in inward current (forward mode) or out-
ward current (reverse mode) according to the depicted changes in NCX activity.
T. Christ et al. / European Journal of Pharmacology 788 (2016) 286–293292SEA0400 was shifted by half a log unit to higher sensitivity upon
[Naþ]i increase from 25 mM to 100 mM (Lee et al., 2004). Thus,
although NCX current amplitudes were higher in samples from AF
than from SR patients, SEA0400 inhibited human atrial NCX cur-
rent only under conditions of high intracellular Naþ .
In our view, modulators of NCX activity are extremely inter-
esting as potential antiarrhythmic drugs. However, unless block of
NCX can be demonstrated directly in human cardiomyocytes un-
der physiological conditions, any antiarrhythmic efﬁcacy has most
likely some other mechanism than NCX block. Hence, extrapola-
tion from animal models requires great caution.
In conclusion, we have shown that human atrial cardiomyo-
cytes exhibit larger NCX current amplitudes in AF than SR. Al-
though SEA0400 blocks Ni2þ-sensitive current in rat cardiomyo-
cytes, it fails to do so in human atrial cardiomyocytes unless the
intracellular internal Naþ concentration is very high. We speculate
that block of NCX with SEA0400 depends on intracellular Naþ
concentration. Further experiments in human atrial tissue are re-
quired to investigate the efﬁcacy of NCX blockers under physio-
logical conditions in order to estimate their antiarrhythmic po-
tential in atrial ﬁbrillation.
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